您好,欢迎来到上海士研管理咨询有限公司
产业峰会 活动服务 营销服务 专家服务
  • 产业峰会:
    以专业团队对产业和市场客观详实地调研为前提,拥有战略性、系统性、全球性的基因,汇集了领导者关注的热点话题与领袖代表,为您提供“一站式”的对话、分享、社交平台!
  • 活动服务:
    致力于成为全球最专业的产业峰会活动提供商,为企业和机构的产业性峰会活动提供一站式专业服务,从调研策划到定制邀请、从营销推广到运营组织,还有项目管理,每项服务都由经验丰富的专业团队匹配长期沉淀的产业资源予以卓越执行,我们注重建立长期而深入的伙伴关系。
  • 营销服务:
    致力于成为全球领先的2B营销服务机构,聚焦产业高端活动、内容、渠道的建设与沉淀,为客户提供一站式整合营销解决方案,助力企业线上线下获客与品牌筑造。我们深信专业团队匹配产业资源带来卓越执行,我们注重建立长期而深入的伙伴关系。
  • 专家服务:
    中国领先的行业专家知识信息服务供应商,为需要专业洞见的商业决策者匹配具有一手经验的行业专家,助力他们以更加明确的目标和坚定的信心做出决策。我们有60万余名专家顾问遍布一百二十多个行业,而且每天还在增加。
会议赞助商
7
2022 - 03 - 08
点击次数:
燃石医学(纳斯达克代码:BNR)成立于2014年,公司使命为“用科学守护生命之光”,专注于为肿瘤精准医疗提供具有临床价值的二代基因测序(NGS)。公司业务及研发方向主要覆盖:1)基于NGS的肿瘤患病人群检测,6年间,燃石累计检测样本超过25万例,在中国拥有最高的市场份额;2)基于NGS的癌症早检,目前已经进入临床验证阶段。燃石医学于2018年7月获国家药品监督管理局(NMPA)颁发的中国肿瘤NGS检测试剂盒第一证,在体外诊断领域具有里程碑式意义。实验室获得广东省临检中心颁发的 “高通量测序实验室”技术审核,以及得美国CLIA和CAP实验室质量体系资质认证。公司将继续致力于开发创新可靠的NGS检测产品,推动肿瘤精准医疗领域的发展。 About Burning RockBurning Rock Biotech Limited (NASDAQ: BNR), whose mission is to Guard Life via Science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, with the leading market share in China and over 250,000 tissue and liquid-based tests completed cumulatively, and ii) NGS-based cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage. In July 2018, Burning Rock received the first approval for a tumor NGS kit by the National Medical Products Administration (NMPA), which is a significant milestone in the field of in vitro diagnosis in China. Burning Rock’s laboratory has obtained the technical certification of “High-throughput sequencing laboratory” issued by Guangdong Center for Clinical Laboratory, and the CLIA and CAP laboratory quality system certification. The company continues to be committed to the development of innovative and reliable NGS testing products and promoting the development of precision medicine in oncology.
8
2022 - 03 - 08
点击次数:
石家庄高新技术产业开发区是1991年3月经国务院批准设立的首批国家级高新区之一,面积78平方公里,现已入驻各类市场主体30000余家,科技型中小企业2665家,高新技术企业1022家。目前,已构筑起以生物医药健康产业为主导,新一代信息技术、先进装备制造、现代服务业协同发展的'1+3'产业体系,在全国25家“生物医药创新型产业集群”中位列第1位,全国生物医药园区创新药物潜力指数10强中位列第5位,全国生物医药园区50强中位列第7位。Shijiazhuang High-tech Industrial Development Zone is one of the first state-level high-tech zones approved by The State Council in March 1991. Covering an area of 78 square kilometers, it has now settled more than 30000 market entities,2665 small and medium-sized sci-tech enterprises and 1022 high-tech enterprises. At present, it has built a '1+3' industrial system dominated by biomedicine and health industry and accompanied by the development of the next-generation IT industry, advanced equipment manufacturing industry and modern service industry.It ranks 1st among the 25 'Biomedical innovative industrial clusters',5th among the top 10 biomedical parks of innovative medicine research and production and 7th among the top 50 national biomedical parks in China.
9
2022 - 03 - 08
点击次数:
长沙通诺信息科技有限责任公司(简称“通诺信息”)成立于2017 年4 月10 日。专注于药学和临床研究信息化建设,致力为国内外制药企业、科研单位和政府机构提供全面综合的信息技术解决方案,助力医药行业信息化升级,推动新药研发进程,保障患者用药安全。通诺信息自主研发ILP(智慧实验室平台)和ICP(智慧临床研究平台)两大信息化平台,为药学与临床研究提供整体解决方案。公司各系统已部署于国内外近100家科研单位、制药企业、CRO公司、临床试验机构和伦理委员会,支撑超过1000个项目和课题顺利开展,成功筛查及入组受试者超过2万人,管理试验样本近50万,3项药学研发项目通过国家局核查。 Changsha Tonoinfo Technology Co., Ltd. (hereinafter referred to as 'Tonoinfo') was established on April 10, 2017. Focusing on the informatization construction of pharmaceutical and clinical research, the company is committed to providing comprehensive information technology solutions for domestic and foreign pharmaceutical enterprises, scientific research institutions and government agencies, to help upgrade the informatization of the pharmaceutical industry, promote the process of new drug research and development, and ensure the safety of drug use for patients.Tonoinfo has independently developed two information platforms, ILP (Intelligent Laboratory Platform) and ICP (Intelligent Clinical Research Platform), to provide overall solutions for pharmaceutical and clinical research. The company's systems have been deployed in nearly 100 domestic and foreign scientific research institutions, pharmaceutical companies, CRO companies, clinical trial institutions and ethics committees, supporting the smooth development of more than 1,000 projects and topics, successful screening and inclusion of more than 20,000 subjects, the management of nearly 500,000 test samples, 3 pharmaceutical research and development projects passed the national inspection.
微信公众号
领导者网络APP
友情链接
Copyright ©2005 - 2017上海士研管理咨询有限公司
犀牛云提供企业云服务